Michael J. Eblan

Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease

E. Sidransky, Mike A. Nalls, Jan Aasly et al. · New England Journal of Medicine · 2009 · 2.1K citations · Full text

Antigen-capturing nanoparticles improve the abscopal effect and cancer immunotherapy

Yuanzeng Min, Kyle C. Roche, Shaomin Tian et al. · Nature Nanotechnology · 2017 · 667 citations · Full text

Nanoparticles, Nanomedicine, Tumor Immunology +6

Cardiac Toxicity After Radiotherapy for Stage III Non–Small-Cell Lung Cancer: Pooled Analysis of Dose-Escalation Trials Delivering 70 to 90 Gy

Kyle Wang, Michael J. Eblan, Allison M. Deal et al. · Journal of Clinical Oncology · 2017 · 419 citations · Full text

Heart Failure, Dose-escalation Trials, Cardiovascular Toxicity +17

Glucocerebrosidase mutations are an important risk factor for Lewy body disorders

Özlem Göker-Alpan, Benoit I. Giasson, Michael J. Eblan et al. · Neurology · 2006 · 227 citations

Lysosomal Protein, Important Risk Factor, Genetics +22

Heart dosimetric analysis of three types of cardiac toxicity in patients treated on dose-escalation trials for Stage III non-small-cell lung cancer

Kyle Wang, Kevin A. Pearlstein, Nicholas D. Patchett et al. · Radiotherapy and Oncology · 2017 · 123 citations · Full text

Medicine, Heart Dosimetric Analysis, Cardiac Toxicity +8